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received funding from the National Institute of
Neurological Disorders and Stroke, National Institutes for
Health (NIH), for the initiation of a multicenter random-
ized clinical trial20 (carotid revascularization endarterec-
tomy versus stent trial [CREST]). Issues related to the
initiation of CREST have been described in prior publica-
tions.21-23
BACKGROUND
Stroke is the third most common cause of death in
North America, and approximately 500,000 new strokes
are reported annually in the United States.24,25 Seventy-
five percent of these strokes occur in the distribution of
the carotid arteries. Among strokes of a thromboembolic
cause, carotid occlusive disease is the most common. The
30-day and 5-year mortality rates for stroke that occurs in
the carotid distribution are 17% and 40%, respectively,24
although as many as 150,300 stroke-related fatalities are
documented annually. The American Heart Association
estimated that the cost of stroke in the United States
approximated 18 billion dollars in 1993.26
CEA reduces the reported incidence of stroke alone and
stroke and death in symptomatic patients with high-grade
≥70% stenoses.1 In addition, recent data presented by the
North American Symptomatic Carotid Endarterectomy
Trial (NASCET) investigators27 has confirmed the efficacy
of CEA for ≥50% carotid stenosis. The procedure also
Carotid endarterectomy is a commonly performed
vascular operation that has emerged as the preferred
method for the treatment of symptomatic1-3 and asymp-
tomatic4,5 patients with high-grade carotid stenosis, dis-
placing optimal medical treatment alone as an ethical
alternative in treating these patients. During the last
decade, however, carotid angioplasty-stenting (CAS) has
been recommended by some clinicians as an alternative to
carotid endarterectomy (CEA) for patients who have
extracranial carotid occlusive disease.6-15 Emergence of a
position of clinical equipoise16 on the relatively equivalent
value of these alternatives, as defined by different special-
ists who treat patients with cerebrovascular insufficiency
by different procedures, has stimulated efforts to deter-
mine efficacy through randomized clinical trials. Two
attempts at randomized clinical trials have been unsuc-
cessful17,18; one effort in the United Kingdom has pro-
ceeded,19 and one major effort in the United States has
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INVITED REVIEWS
Carotid angioplasty-stent: Clinical experience and
role for clinical trials
Robert W. Hobson II, MD, Newark, NJ
Carotid angioplasty-stenting (CAS) is a relatively new endovascular procedure that has been used increasingly in recent
years. Its popularity is due to, at least in part, the perceived advantages of a less invasive treatment for extracranial carotid
occlusive disease. However, valid data that contrast the efficacy of CAS and carotid endarterectomy (CEA), the gold stan-
dard for the treatment of symptomatic carotid stenosis, are not available.
The Carotid Revascularization Endarterectomy versus Stent Trial (CREST) will contrast the relative efficacy of CAS with
CEA in the prevention of stroke, myocardial infarction, or death during a 30-day periprocedural period or an ipsilateral
stroke thereafter during a follow-up period extending up to 4 years. Stroke events will be verified by an adjudication
committee masked to the assigned treatment. Secondary outcomes will (1) describe differential efficacy of CAS and CEA
in men and women, (2) contrast periprocedural (30-day) morbidity and postprocedural (after 30-days) morbidity and
mortality rates, (3) estimate and contrast the restenosis rates of the two procedures, (4) evaluate the differences in mea-
sures of health-related quality of life and cost effectiveness, and (5) identify subgroups of participants at differential risk
for CAS and CEA. The primary eligibility criterion is a >50% stenosis of the carotid artery in patients with ipsilateral
amaurosis fugax (transient monocular blindness), transient ischemic attack, or nondisabling stroke. Men and women will
be eligible for the trial, but patients with medical conditions likely to limit their participation during the follow-up or
to interfere with outcome evaluation will be excluded. After a credentialing and training phase, 2500 patients will be
randomized to the treatments. Statistical analysis of the primary outcome will use standard survival methods. (J Vasc
Surg 2001;33:S117-23.)
reduces the incidence of combined neurologic events in
male patients with >50% asymptomatic stenosis4 and of
ipsilateral stroke or any periprocedural stroke or death in
patients with >60% asymptomatic stenosis.5 Although
CAS has been proposed as an alternative to CEA, the
safety and clinical effectiveness of CAS has not been estab-
lished, and no prospective comparisons of CAS and CEA
have been conducted in this country. Furthermore, a
recently published Science Advisory from the American
Heart Association28 concluded that “…with few excep-
tions, use of carotid stenting should be limited to well-
designed, well-controlled randomized studies with careful
dispassionate oversight.”
CEA, performed with a low periprocedural compli-
cation rate, is the only form of mechanical cerebral revas-
cularization for which definitive evidence of clinical
effectiveness has been reported. In the NASCET data,1
life-table estimates of the cumulative risk of stroke at 2
years were 26% in the medical group versus 9% in the
surgical group (absolute risk reduction [±SE], 17% ±
3.5%; P < .001). The corresponding estimates for major
or fatal ipsilateral stroke were 13.1% versus 2.5%
(absolute risk reduction [±SE], 10.6% ± 2.6%; P < .001)
and for any stroke or death were 32% versus 16%
(absolute risk reduction [±SE], 16.5% ± 4.2%; P < .001).
Complementary findings were reported in the European
carotid surgery trial2 and the Veterans Affairs symp-
tomatic endarterectomy trial.3 Although recent, the pre-
sentation of data by the NASCET investigators on
patients with symptomatic disease23 also has confirmed
the efficacy of CEA in male patients with 50% to 69%
stenosis, the benefit was not confirmed in female patients
with the same degree of stenosis. In the asymptomatic
carotid atherosclerosis study (ACAS),5 after a median
follow-up of 2.7 years, the aggregate risk over 5 years for
ipsilateral stroke and any periprocedural stroke or death
was estimated to be 5.1% for surgical patients and 11%
for patients treated medically (aggregate risk reduction,
53%; 95% confidence interval [CI], 22%-72%). Results
from these trials have reshaped current indications for
CEA worldwide.
CAROTID ANGIOPLASTY AND ANGIOPLASTY-
STENTING
Numerous case reports and clinical series have been
published.6-15 The first report of a multicenter prospective
protocol-based study of CAS, the North American
Percutaneous Transluminal Angioplasty Register,8,9 was
published in 1993. Interim results were reported on 165
angioplasty procedures in 147 symptomatic nonsurgical
patients. The average stenosis before angioplasty was 84%
(range, 70%-99%). The average stenosis immediately after
angioplasty was 37% (P < .01). This corresponded to an
immediate success rate of 83% (95% CI, 76%-88%). Death
from all causes occurred in 3% of procedures, and stroke
occurred in an additional 6% of procedures. The 30-day
combined rate of death and stroke from all causes was 9%
(95% CI, 5%-15%). Data concerning the rate of restenosis
in 44 lesions with angiographic follow-up at a mean of
260 days also have been reported.9 The definition of
restenosis was angiographic documentation of >70%
stenosis. Of the 37 lesions that were less than the original
70% stenosis after the initial dilatation, restenosis occurred
in eight lesions (22%; 95% CI, 10%-38%). Of the patients
who had restenosis, five of eight patients (63%) were
symptomatic at the time of follow-up. Cox proportional
hazards modeling demonstrated that symptoms and the
degree of stenosis before angioplasty were independent
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Table I. Protocol for the CAS procedure
• Transfemoral 8F introducer sheath; open carotid cannulation considered in presence of severe aortoiliac disease; preprocedural 
aspirin and ticlopidine (Ticlid) or clopidogrel (Plavix)
• 0.035-inch J-guidewire with moveable core to aortic arch; heparinization to ACT of 225-250 seconds
• NH-2 Vitek* catheter for cannulation of aortic arch branches
• 0.035-inch coated Terumo† long-exchange guidewire to external carotid artery; occasional use of the 0.035-inch Amplatz† stiff 
guidewire recommended to advance the NH-2 catheter or the 8F guide sheath
• 7F or 8F (internal diameter) guide sheath (100 cm length) to common carotid artery proximal to lesion
• 0.018-inch guidewire to cross common internal carotid stenosis
• 3- or 4-mm low profile balloon for pre-stent dilatation
• Deployment of 8 × 20–mm or 10 × 20–mm WallStent endoprosthesis over 0.018-inch wire
• Poststent dilatation with 5- or 6-mm balloons
• Intermittent hand-injection angiography during procedure; use bony landmarks for balloon and stent placements
• Removal of sheath once ACT is less than 150 seconds; continuation of aspirin, although Ticlid or Plavix is discontinued 3 weeks
after CAS
*Cook Cardiology, Bloomington, Ind.
†Boston Scientific, Natick, Mass.
ACT, Action clotting time.
Modified from Hobson RW II, Goldstein JE, Jamil Z, et al. Carotid restenosis: operative and endovascular management. J Vasc Surg
1999;29:228-38. With permission.
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predictors of angiographic restenosis in follow-up. These
data suggested that restenosis after angioplasty alone
would be a significant problem and stimulated clinicians to
perform stenting after angioplasty as a routine practice. 
In 1996, Diethrich et al10 reported the results of CAS
in 110 symptomatic patients with ≥70% stenoses from a
single institution. One procedure failed (0.9%) for techni-
cal reasons and was converted to CEA. Two deaths (1.8%)
occurred (one from stroke and one from a cardiac event).
Seven strokes (two major [1.8%] and five minor [4.5%])
and five transient neurologic events (4.5%) occurred. On
the basis of this early experience, the authors concluded
that the incidence of periprocedural neurologic complica-
tions was excessive. In an accompanying editorial,
Diethrich29 suggested that CAS be restricted to cases of
carotid restenosis after prior CEA, instances in which the
internal carotid stenosis was anatomically higher than
readily treated by CEA and radiation-induced stenosis.
A larger prospective protocol-based study of CAS in
204 patients was reported by Mathur et al.11 Ages ranged
from 36 to 86 years; 75% of the patients had significant
coronary artery disease, and 70% of the patients had med-
ical comorbidities that would have made them ineligible for
the NASCET study. Of the 238 arteries that were treated
(204 patients), 145 arteries (61%) were found in patients
with ipsilateral symptoms (60 strokes; 85 transient ischemic
attacks [TIAs]); 93 arteries were treated in asymptomatic
patients. Nine percent of the patients had an occluded con-
tralateral carotid artery, and 15% of the patients had
restenosis after previous CEA. Eighteen percent of the
patients had complex lesions with ulcerated plaques.
Technical success was achieved in 99% of patients. In two
patients, the carotid could not be accessed by the trans-
femoral approach. In one patient, the procedure was
aborted after initial angiography was complicated by an air
embolism. Of the 204 patients, there was one death (0.5%)
and two major strokes (0.98%; NIH stroke scale, >4, with
residual disability >30 days). One stroke was due to the sin-
gle episode of stent thrombosis, and the other stroke was
due to a cardiogenic embolus that caused a contralateral
stroke on the second postprocedural day. Minor strokes
(NIH stroke scale, <3, with resolution within 30 days) were
observed in 15 patients (7.4%). During follow-up, one
minor ischemic stroke has occurred in these 204 patients.
Three patients have experienced TIAs, with no evidence of
stent restenosis. Four patients died during follow-up (one
congestive heart failure, one pneumonia, one intracranial
hemorrhage [patient not receiving anticoagulation ther-
apy], one renal failure). Repeat carotid imaging (angiogra-
phy or ultrasound scanning) has been performed in 75% of
patients who have reached 6 months of follow-up.
Restenosis (>70% diameter reduction) has been docu-
mented in five of the 104 patients (5%) who were restudied.
Stent deformation occurred in 14% of the balloon-expand-
able stents that were deployed. Consequently, only self-
expanding stents have been used by the authors thereafter.
As a result of these data, a self-expandable stent has been
recommended for use by the CREST investigators.
Recently, Roubin et al12 updated their previous
report.11 These data included 271 procedures in 231
patients (139 symptomatic patients; 60%). Of the arteries
treated, 214 arteries (79%) were excluded by NASCET
and ACAS criteria. Major strokes occurred in two patients
(0.9%), and minor strokes occurred in 17 patients (7.4%);
however, among NASCET-ACAS eligible patients, only
one minor stroke (1.8%) was reported. Predictors of
stroke in the overall clinical update included advanced age,
lesion severity, and long/multiple lesions. In a recent
update on 40 NASCET-eligible patients, Gomez et al15
reported one transient neurologic event (2.5%) and no
deaths, major stroke, or myocardial infarctions. These
investigators suggested a comparability of complications
between CAS and CEA.
Currently, one randomized clinical trial to compare the
efficacy of CAS and CEA is on-going in Europe, the
carotid and vertebral artery transluminal angioplasty
study.19 Investigators17 are comparing surgical interven-
tion and angioplasty for treatment of carotid and vertebral
occlusive lesions. Martin Brown, MD, principal investiga-
tor for the carotid and vertebral artery transluminal angio-
plasty study, presented the results from phase I of a
multicentered trial during the American Heart Association
International Stroke meeting in New Orleans, La,
February 10-13, 2000. Among 504 patients who were ran-
domized primarily to angioplasty alone and considered
suitable candidates for CEA, 30-day stroke and death rates
were comparable (CEA group, 6.3%; CAS group, 6.4%).
Phase II will be initiated later this year and will use angio-
plasty-stenting in all symptomatic carotid cases. These are
the only data available about cases that were randomized to
CEA or CAS; however, their influence may be blunted by
the somewhat higher than expected complication rate in
the CEA group. Alberts et al17 described the methods of
another randomized clinical trial that compared carotid
stenting versus endarterectomy in symptomatic patients
(stenosis, 50%-99%) that was sponsored by the Schneider
Corporation (now Boston Scientific Vascular, Natick,
Mass, manufacturers of the WallStent endoprosthesis). The
stated aim of the trial was to determine whether carotid
stenting is equivalent to CEA in the prevention of any ipsi-
lateral stroke, periprocedural death (within 30 days), or
vascular death within 1 year of treatment. However, this
trial has been discontinued because of procedural and
recruitment difficulties. The other attempt at a randomized
trial was plagued by an excessively high complication rate
in the CAS group, which resulted in its discontinuance.18
Conclusions regarding the results of these retrospec-
tive analyses and initial clinical trial data await further
review. However, it now appears that, in selected patients,
CAS can be used to treat extracranial carotid stenosis in
NASCET-eligible patients with periprocedural complications
similar to rates of perioperative complications for CEA.
CURRENT PRACTICE: TECHNICAL 
CONSIDERATIONS
On the basis of the conclusions of a multidisciplinary
panel at the recent Montefiore Vascular Symposium,30
subgroups of patients (including high-risk patients with
significant medical comorbidities and patients with carotid
restenosis after previous CEA, anatomically inaccessible
lesions above C2, and radiation-induced stenoses) should
currently be considered for CAS. As an example, our
group12 recently documented the comparability of results
between CAS and surgical treatment for restensosis after
primary CEA. However, in the absence of randomized clin-
ical trial methods,5 we are currently unwilling to expand the
use of CAS beyond these defined subgroups of patients.11
We have restricted our use of CAS to patients with
carotid restenosis after CEA31 and to patients with high-risk
medical comorbidities.32 Symptomatic or asymptomatic
carotid restenosis after CEA is relatively uncommon and is
generally attributed to myointimal hyperplasia during the
early postoperative period (within 36 months) or recurrent
atherosclerosis thereafter.33-37 Surgical treatment of carotid
restenosis is controversial for two major reasons. First, indi-
cations for operative treatment in the asymptomatic patient
with high-grade ≥80% restenosis remain controversial
because of the low risk of stroke or progression to total
occlusion.33,38,39 Second, reoperation is associated with an
increased risk of perioperative neurologic events and cranial
nerve palsies.35,40,41 Because of these issues, some
authors42-45 recommend CAS as an alternative to operative
treatment. However, the lack of efficacy data that compares
endovascular treatment with CEA has created additional
controversy in the choice of treatment among specialists
who have patients with carotid restenosis and patients with
primary atherosclerotic occlusive disease.
We prospectively collected data and intervened using
endovascular techniques on patients with symptomatic
and asymptomatic ≥80% carotid restenosis because of
myointimal hyperplasia for the purpose of defining techni-
cal feasibility and periprocedural outcomes.31 Technical
considerations in the performance of CAS are outlined in
Table I. Examples of arteriograms before and after the
procedure (Figs 1 and 2) show the placement of an 8 or
10 mm × 20 mm WallStent endoprosthesis. In each case,
4-mm low-profile balloons were used to initially dilate the
lesions, which was followed by the placement of appropri-
ately sized stents with poststent balloon dilatation to
obtain the final result. Intravascular ultrasound scanning
was used to insure adequate apposition of the stent to the
arterial wall. In these cases and all but one other case,
stents were placed across the carotid bifurcation. Serial
duplex ultrasonography has demonstrated patency of all
external and internal carotid arteries.
In an expanded series of 46 patients who underwent
50 CAS procedures,32 all procedures were completed
technically. One 72-year-old woman with severe coexist-
ing coronary artery disease had undergone coronary
angioplasty-stenting during the week before a right
carotid angioplasty-stent procedure for symptomatic high-
grade carotid stenosis. Discharged on the morning after
the CAS procedure, the patient was alone at home and
died suddenly 10 days later, presumably because of an
acute myocardial infarction or cardiac arrhythmia. Hers
was the only death (2.2%) in our overall series of 50 CAS
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Fig 1. A, Preprocedural stenosis in an asymptomatic patient. B,
Result after CAS with an 8 × 20–mm WallStent endoprosthesis
shown by means of selective arteriograms. (From Hobson RW II,
Goldstein JE, Jamil Z, et al. Carotid restenosis: operative and
endovascular management. J Vasc Surg 1999;29:228-38. With
permission.)
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procedures. All patients were discharged on the morning
after the procedure, and no periprocedural strokes or
other deaths have been observed. Appearance of high-
grade ≥80% in-stent restenosis32 has now been docu-
mented in four of our 50 CAS procedures (8%) after 18
± 10 months of follow-up. Cases have been treated by
angioplasty (n = 3 cases) or angioplasty and restenting
(n = 1 case), and all patients are asymptomatic without
recurrent restenosis.
Based on our experience with CAS and on a review of
results from retrospective analyses and one prospective
clinical trial, these data suggest that an efficacy trial that
would compare the results of CEA and CAS procedures
should proceed in this country. The CREST investigators
have been funded to use a single stent in the trial; how-
ever, they anticipate the use of run-in phase data and high-
risk registry cases to introduce new stents and cerebral
protection devices during the course of the trial.
CREST ORGANIZATIONAL PLAN
Stimulated by our clinical experience and the refer-
enced reports, the CREST investigators received approval
for funding from the National Institute of Neurological
Disorders and Stroke, NIH, for a trial to compare the effi-
cacy of CEA and CAS in symptomatic patients with high-
grade ≥70% stenosis. Recent discussions have been
completed to reduce the threshold lesion to ≥50% stenosis.
However, recognizing that CAS is a relatively new proce-
dure, each participating center will be required to complete
a credentialing phase to reassure clinicians that the safety of
these procedures has been reviewed and established before
the randomized phase of the trial proceeds.
Assuming that a credentialing phase that requires the
performance of up to 20 interventional procedures at each
of 50 or more participating centers is completed to the
satisfaction of the study’s Interventional Management
Committee, randomization of patients between the two
treatments will then proceed. The primary outcome
events for this clinical trial will include (1) any stroke,
myocardial infarction, or death during the 30-day periop-
erative or periprocedural period or (2) ipsilateral stroke
after 30 days. Endpoints will be reviewed by an
Adjudication Committee, blinded to the assigned treat-
ment. Stroke will be determined by a positive TIA/stroke
questionnaire that is confirmed by an evaluation of a neu-
rologist. Myocardial infarction will be determined by elec-
trocardiography and enzyme abnormalities. Secondary
goals include (1) to describe differential efficacy of the two
treatments in men and women, (2) to contrast periopera-
tive procedural (30-day) morbidity and postprocedural
(after 30 days) mortality rates for the CEA and CAS pro-
cedures, (3) to estimate and contrast the restenosis rates
for the two procedures, (4) to identify subgroups of par-
ticipants at differential risk for the two procedures, and (5)
to evaluate differences in health-related quality of life
issues and cost effectiveness.
A differential efficacy assessment of CEA and CAS that
is based on gender is a secondary goal for CREST. In
patients with high-grade asymptomatic stenosis that were
reported by ACAS, CEA offered a 66% reduction in events
over a 5-year period for men, but only a 17% reduction for
women.5 In NASCET, although no differential gender
effects were reported among symptomatic patients with
>70% stenosis, male patients demonstrated greater benefit
after CEA than women for 50%-69% stenosis.27 Although
the causes for these examples of differential efficacy
between genders are not well understood, the effect may
Fig 2. A, Preprocedural stenosis in an asymptomatic patient. B,
Result after CAS with a 10 × 20–mm WallStent endoprosthesis
shown by means of selective arteriograms. (From Hobson RW II,
Goldstein JE, Jamil Z, et al. Carotid restenosis: operative and
endovascular management. J Vasc Surg 1999;29:228-38. With
permission.)
A
B
be attributed to a higher complication rate for CEA in
women, possibly caused by their reported smaller arterial
sizes and a greater surgical morbidity. Unfortunately, nei-
ther ACAS or NASCET suspected the possibility of a dif-
ferential gender effect. However, given the results of these
two randomized clinical trials, a requirement for a priori
plans to evaluate the possibility of a differential gender
effect has become an important component of CREST.
Centers are being selected with a goal as high as 50% for
women in the randomized sample of patients and a mini-
mum of 40%.
Patients will be evaluated at baseline, at 24 hours
before the procedure, at 30 days, at 6 months, and there-
after at 6-month intervals. Baseline procedures will
include a brief medical history and physical examination, a
risk factor evaluation, the performance of neurologic sta-
tus questionnaires, a neurologic examination, a electrocar-
diogram, and a baseline carotid duplex scan. The 30-day
follow-up will include evaluation of the neurologic status
through questionnaires, a electrocardiogram, and a fol-
low-up carotid duplex scan. All 6-month follow-up visits
will include a brief physical examination, the completion
of the neurologic questionnaire, a risk factor evaluation,
and a carotid duplex scan. All patients with a positive neu-
rologic status questionnaire will be evaluated by a neurol-
ogist. The sample size for the study is approximately 2500
symptomatic patients, which will be sufficient to detect a
relative difference of 25% to 30% between treatment
groups. Lesser differences would be considered suffi-
ciently small to declare the treatments equivalent.
Opinions have varied about the participation of vascu-
lar surgeons in randomized clinical trials on CEA.
Although the value of our participation has been recom-
mended,26 the emergence of clinical equipoise16 between
treatment groups (as supported by a rigorous credentialing
phase of CREST) should reassure our colleagues about
their participation and the ethical conduct of this trial.
CONCLUSIONS
Current clinical practice dictates that CAS be consid-
ered in limited subsets of patients. The conducting of clin-
ical trials (CREST and others) will provide level I and II
evidence on which to establish a firm clinical recommen-
dation. Until these data are available during the next sev-
eral years, the performance of CAS should be limited to
randomized clinical trials and defined unique subsets of
high-risk patients. CEA continues to be recommended for
the treatment of most patients with symptomatic and
asymptomatic extracranial carotid occlusive disease.
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